Farklı iki doz asetilsalisilik asidin sağlıklı gönüllülerde serum nitrik oksit, asimetrik dimetilarjinin ve homosistein seviyelerine etkileri

Amaç: Bu çalışmanın amacı sağlıklı gönüllülerde ASA’nın serum nitrik oksit (NO), asimetrik dimetilarjinin (ADMA)ve homosistein seviyelerine etkisini belirlemektir.Yöntem ve gereç: Çalışmada toplam 26 sağlıklı gönüllü yer aldı. İki ay süresince katılanlardan 13’ü (5K, 8E) günde100 mg ve 13’ü (5K, 8E) günde 150 mg ASA aldı. ASA tedavisinden önce ve bir ve iki ay sonra serum NO, ADMAve homosistein seviyeleri ASA tedavisinden önce ve bir ve iki ay sonra serum NO, ADMA ve homosistein seviyeleriölçüldü.Bulgular: 150 mg ASA kullanan grubun ADMA seviyeleri iki aylık tedavinin sonunda anlamlı olarak azalmıştı (P <0,05). ASA tedavisinden sonra başlangıç değerleri ile karşılaştırıldığında her iki grubun NO seviyeleri hafi f ama önemsizartmış homosistein seviyeleri ise hafi f azalmıştı.Sonuç: Bulgularımız ASA tedavisinin ADMA seviyelerini doz ve zamana bağlı olarak azalttığını gösterdi. Bu faydalı etkikardiovasküler hastalıkların önlenmesine katkıda bulunuyor olabilir.

Anahtar Kelimeler:

Asetilsalisilik asit, nitrik oksit, asimetrik dimetilarjinin, homosistein, sağlıklı gönüllüler

Eff ects of two diff erent doses of acetylsalicylic acid on serum nitric oxide, asymmetric dimethylarginine, and homocysteine levels in healthy volunteers

To examine the effects of ASA on serum nitric oxide (NO), asymmetric dimethylarginine (ADMA), and homocysteine levels in healthy volunteers. Materials and methods: Totally, 26 apparently healthy volunteers were enrolled in the study. Of the participants, 13 (5F, 8M) received 100 mg of ASA daily and 13 (5F, 8M) received 150 mg of ASA daily for 2 months. Serum NO, ADMA, and homocysteine levels were measured before and 1 and 2 months after ASA treatment Serum NO, ADMA, and homocysteine levels were measured before and 1 and 2 months after ASA treatment. Results: ADMA levels of the group receiving 150 mg of ASA were significantly reduced after 2 months of treatment (P < 0.05). NO levels of both groups were slightly but not significantly increased and homocysteine levels of both groups were slightly reduced after ASA treatment compared to the baseline values. Conclusion: Our findings indicate that ASA treatment reduces ADMA levels dose and time dependently, a beneficial effect that may contribute to the prevention of cardiovascular diseases.

Keywords:

nitric oxide, asymmetric dimethylarginine, homocysteine, healthy volunteers, Acetylsalicylic acid,

PDF

___

Lièvre M, Cucherat M. Aspirin in the secondary prevention of cardiovascular disease: an update of the APTC meta-analysis, Fundam Clin Pharmacol 2010; 24: 385-91.
Mehta JL. Salutary eff ects of aspirin in coronary artery disease are not limited to its platelet inhibitory eff ects. Clin Cardiol 1998; 21: 879-84.
Pepine CJ. Th e impact of nitric oxide in cardiovascular medicine: untapped potential utility. Am J Med 2009; 122: 10- 15.
De Gennaro Colonna V, Bianchi M, Pascale V, Ferrario P, Morelli F, Pascale W et al. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. Med Sci Monit 2009; 15: RA91-101. 5. Bode-Böger SM, Martens-Lobenhoff er J, Täger M, Schröder H, Scalera F. Aspirin reduces endothelial cell senescence. Biochem Biophys Res Commun 2005; 334: 1226-32.
Taubert D, Berkels R, Grosser N, Schröder H, Gründemann D, Schömig E. Aspirin induces nitric oxide release from vascular endothelium: a novel mechanism of action. Br J Pharmacol 2004; 143: 159-65.
Grosser N, Schröder H. Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway. Arterioscler Th romb Vasc Biol 2003; 23: 1345-51.
Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652-8.
Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001; 104: 2569-75.
Selley ML. Homocysteine increases the production of
asymmetric dimethylarginine in cultured neurons. J Neurosci Res 2004; 77: 90-3.
Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88: 1201-3.
Chamberlain KL. Homocysteine and cardiovascular disease: a review of current recommendations for screening and treatment. J Am Acad Nurse Pract 2005; 17: 90-5.
Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J et al. DACH-LIGA homocystein (German, Austrian and Swiss Homocysteine Society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med 2003; 41:1392-403.
Sydow K, Münzel T. ADMA and oxidative stress. Atheroscler Suppl 2003; 4: 41-51.
Wu R, Lamontagne D, de Champlain J. Antioxidative properties of acetylsalicylic Acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation 2002; 105: 387-92.
Hofmann T. Risk management of coronary artery disease-- pharmacological therapy. Wien Med Wochenschr 2004; 154: 266-81.
Chen BM, Xia LW, Zhao RQ. Determination of N(G),N(G)- dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 692: 467-71.
Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092-5.
Saran R, Novak JE, Desai A, Abdulhayoglu E, Warren JS, Bustami R et al. Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study. Nephrol Dial Transplant 2003; 18: 2415-20.
Jiang JL, Li Ns NS, Li YJ, Deng HW. Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Br J Pharmacol 2002; 135: 1175- 82.
Kurban S, Mehmetoglu I. Eff ects of acetylsalicylic acid on serum paraoxonase activity, Ox-LDL, coenzyme Q10 and other oxidative stress markers in healthy volunteers. Clin Biochem 2010; 43: 287-90.
Deng S, Deng PY, Jiang JL, Ye F, Yu J, Yang TL et al. Aspirin protected against endothelial damage induced by LDL: role of endogenous NO synthase inhibitors in rats. Acta Pharmacol Sin 2004; 25: 1633-9.
Yi TN, Zhao HY, Zhang JS, Shan HY, Meng X, Zhang J. Eff ect of aspirin on high glucose-induced senescence of endothelial cells. Chin Med J (Engl) 2009; 122: 3055-61.
Hennekens CH, Schneider WR, Pokov A, Hetzel S, DeMets D, Schröder H, et al. Usual doses of aspirin markedly increase nitric oxide formation in humans. Circulation 2009; 120: 405.
Oberle S, Polte T, Abate A, Podhaisky HP, Schröder H. Aspirin increases ferritin synthesis in endothelial cells: a novel antioxidant pathway. Circ Res 1998; 82: 1016-20.
Podhaisky HP, Abate A, Polte T, Oberle S, Schröder H. Aspirin protects endothelial cells from oxidative stress—possible synergism with vitamin E. FEBS Lett 1997; 417: 349-51.
Zhao L, Gray L, Leonardi-Bee J, Weaver CS, Heptinstall S, Bath PM. Eff ect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke. Platelets 2006; 17: 100-4.
Girish GV, Sinha N, Chakraborty K, Bhattacharya G, Kahn NN, Sinha AK. Restoration by aspirin of impaired plasma maspin level in human breast cancer, Acta Oncol 2006; 45: 184- 7.
Schroecksnadel K, Frick B, Winkler C, Wirleitner B, Schennach H, Fuchs D. Aspirin downregulates homocysteine formation in stimulated human peripheral blood mononuclear cells. Scand J Immunol 2005; 62: 155-60.
Clarke R, Harrison G, Richards S. Vital Trial Collaborative Group. Eff ect of vitamins and aspirin on markers of platelet activation, oxidative stress and homocysteine in people at high risk of dementia. J Intern Med 2003; 254: 67-75.